Overview

Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.

Status:
Recruiting
Trial end date:
2022-04-14
Target enrollment:
Participant gender:
Summary
The aim of our study will be to assess in an open-label, multicenter, randomized controlled trial whether a tailored therapy guided by a non-invasive antibiotic susceptibility test on stool samples achieves higher Helicobacter eradication rates than an empiric antibiotic regimen. For this purpose, consecutive patients with dyspeptic symptoms, diagnosis of Helicobacter pylori infection and naïve to eradicating treatments will be allocated to either of the two intervention arms.
Phase:
Phase 3
Details
Lead Sponsor:
University of Bari
Treatments:
Amoxicillin
Anti-Bacterial Agents
Bismuth
Bismuth tripotassium dicitrate
Clarithromycin
Levofloxacin
Metronidazole
Ofloxacin
Pantoprazole
Rifabutin
Tetracycline